Time-of-day immunotherapy for advanced melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether giving immunotherapy at a specific time of day can improve its effectiveness for advanced melanoma that cannot be removed by surgery. It may help you if you have stage IV melanoma and have not had immunotherapy in the last year.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IV melanoma that cannot be removed by surgery.
- Your melanoma type is cutaneous, acral, or mucosal (not uveal).
- You have not had immunotherapy in the last year.
- Any brain metastases must be smaller than 2 cm, not causing symptoms, and not bleeding.
- You are generally active and able to care for yourself (ECOG 0 or 1).
- You are not taking high doses of steroids (more than 10 mg prednisone daily) and do not have an active autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies the timing of a standard immunotherapy combination for advanced melanoma that cannot be removed by surgery or has spread. It aims to understand how timing affects treatment results.
This trial tests whether giving immunotherapy at different times of the day (chrono-immunotherapy) is better for people with advanced melanoma. It looks at how timing might affect how well the treatment works and side effects.
This trial tests whether getting your immunotherapy infusion in the morning or in the afternoon makes any difference in how well it works. If you have certain types of advanced cancer and are about to start a standard FDA-approved immunotherapy, this study may help you and others by finding the best time of day for treatment.
This early trial tests CBL0137 along with ipilimumab and nivolumab (two immune-based cancer medicines) in people with stage III or possibly stage IV melanoma that can be biopsied. It may help shrink melanoma and improve immune control, while also learning how safe and effective this combination is.
This trial tests a combination of two immunotherapy drugs with standard chemotherapy (bevacizumab, albumin-bound paclitaxel, and carboplatin) for people with advanced acral or mucosal melanoma. The goal is to see if this combination can shrink tumors or slow the cancer's growth better than current treatments.
This study tests how well immunotherapy drugs like pembrolizumab and nivolumab work for people with advanced melanoma that has spread. It aims to find markers that predict treatment response.
Hear when a new Clinical Stage IV Cutaneous Melanoma AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.